Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Launched by CURE CMD · Jul 26, 2011
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
The Congenital Muscle Disease Study, also known as CMDPROS, is a long-term research project aimed at understanding various types of congenital muscular dystrophy and related conditions. Over the next 10 years, researchers will collect information from patients and their families to track health outcomes and identify any side effects from treatments. By registering in the Congenital Muscle Disease International Registry (CMDIR) at www.cmdir.org, participants can help build a global database that will aid in raising awareness, improving care standards, and potentially leading to new treatments for these conditions.
To be eligible for this study, individuals must have specific types of congenital muscular dystrophy, congenital myopathy, or congenital myasthenic syndrome. Participants will be asked to fill out a survey and provide medical records related to their diagnosis and treatment. Importantly, there is no need to travel for this study, making it easier for families to participate. Your involvement can significantly contribute to the understanding and future management of these muscle diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Alpha 7/Alpha 9 Integrin Related Myopathy Collagen VI Related Myopathy (Ullrich through Bethlem CMD) Alpha-Dystroglycan Related Muscular Dystrophy (Dystroglycanopathy, WWS, MEB, Fukuyama, FKRP, LGMD2I, LGMD2K, LGMD2M, LGMD2N, LGMD2O) Choline Kinase B Receptor Emery-Dreifuss Muscular Dystrophy (EDMD, LGMD1B, LMNA, Emerin, FHL1, SYNE1, SYNE2, TMEM43) LAMA2 Related Muscular Dystrophy (Laminin Alpha 2 related dystrophy/MDC1A/Merosin deficient) LMNA Related Muscular Dystrophy (Laminopathy/LaminA/C, L-CMD, Emery Dreifuss muscular dystrophy) RYR1 Related Myopathy (with dystrophic presentation, including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) SEPN1 Related Myopathy (Rigid Spine Muscular Dystrophy/RSMD1, Congenital Fiber Type Disproportion, Mallory Weiss Body Desmin, Multi-minicore Myopathy) SYNE1 (Nesprin Related Muscular Dystrophy) Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap) Congenital Muscular Dystrophy Not Otherwise Specified (including Merosin Positive) Titin Related LGMD/CMD, LGMD2J Actin Aggregation Myopathy Cap Disease Central Core Disease (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Centronuclear Myopathy (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Congenital Fiber Type Disproportion (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Core Rod Myopathy Hyaline Body Myopathy Multiminicore Myopathy Myotubular Myopathy Nemaline Myopathy Reducing Body Myopathy RYR1 Related Myopathy (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Spheroid Body Myopathy Titin Related Myopathy, Titin Related Dialated Cardiomyopathy, LGMD2J Tubular Aggregate Myopathy Zebra Body Disease Myopathy Congenital Myopathy Not Otherwise Specified Congenital Myasthenic Syndrome Escobar Syndrome Myofibrillar Myopathy
- Exclusion Criteria:
- • Charcot Marie Tooth Duchenne/Becker Muscular Dystrophy Facioscapulohumeral Dystrophy/FSHD Kennedy's Disease LGMD-1A (TTID) LGMD-1C (CAV3, Caveloin 3, Caveolinopathy, LQT9, VIP21) LGMD-1D (7q) LGMD-1E (6q23) LGMD-1F (7q32.1-q32.2) LGMD-1G (4q21) LGMD-2A (CAPN3/Calpainopathy) LGMD-2B (DYSF/Dysferlinopathy/Miyoshi Myopathy) LGMD-2C (SGCG) LGMD-2D (SGCA) LGMD-2E (SGCB) LGMD-2F (SGCD) LGMD-2L (AN05/Anoctamin 5) Lipodystrophy Myotonic Dystrophy Oculopharyngeal Muscular Dystrophy Spinal Muscular Atrophy
About Cure Cmd
Cure CMD is a nonprofit organization dedicated to advancing research and developing innovative therapies for congenital muscular dystrophies (CMD). Through collaborative partnerships with academic institutions, industry leaders, and patient advocacy groups, Cure CMD focuses on accelerating the discovery of effective treatments and improving the quality of life for individuals affected by CMD. Their commitment to scientific rigor and patient-centered approaches drives a multifaceted agenda that includes funding research initiatives, fostering clinical trials, and enhancing awareness of this rare group of muscular disorders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lakewood, California, United States
Patients applied
Trial Officials
Gustavo Dziewczapolski, PhD
Study Chair
CureCMD, CMDIR
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials